SLC5A2 and heart failure: For example, the EMPA-REG OUTCOME, CANVAS program, and DECLARE-TIMI 58 trials have all showed reductions in mortality and heart failure hospitalization patients with T2DM after treatment with SGLT2 inhibitors (Fitchett et al., 2016; Neal et al., 2017; Fitchett et al., 2019; Wiviott et al., 2019).